Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Brainify.AI logo — AI biomarker platform for a novel treatment developed for de...

Brainify.AI

AI biomarker platform for a novel treatment developed for depression. Part of J&J Jlabs and Merck DSS.

Founded 2021 United States New York, United States 11 employees Pre Seed Total: $1.60M AI, Health Care +2

General Information

Company Name Brainify.AI
Founded Year 2021
Location United States New York, United States +1
Employees 11
Industries AI, Health Care, Pharmaceutical +1
Funding Stage Pre Seed
Social

Get notified when Brainify.AI moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Brainify.AI

Brainify.AI, founded in 2021, is revolutionizing the pharmaceutical landscape with its cutting-edge AI biomarker platform. This innovation, designed specifically for the development of novel treatments for depression, is positioned to enhance the likelihood of new treatment approvals and boost drug efficacy. Positioned uniquely at the crossroads of multiple burgeoning industries — AI, Health Care, Pharmaceutical, and Machine Learning — Brainify.AI operates out of the United States.

Endorsed by influential partners, Brainify.AI is a proud member of J&J Jlabs and Merck DSS, and is bolstered by investments from prominent backers including Merck GHI Fund, Northpond, and Kodori VC. The company recently secured a $1.00 million Pre Seed Round investment as of January 10, 2023, showcasing robust confidence in its vision and potential within the competitive realm of depression treatment solutions.

Taxonomy: AI biomarker platform, depression treatment, drug development, AI/ML, EEG biomarker, clinical trials, R&D efficiency, patient outcomes, PlaceboInsight AI, TherapyInsight AI, CleanSpectrum AI, pharmaceutical innovation, investment backed, clinical data analysis

Services & Products

Developing and applying AI models for precision neuroscience
analyzing brain data to identify EEG biomarkers for neurological disorders and drug development.

Target Customers

Clinics pharmaceutical companies research institutions and professionals in the healthcare and neuroscience fields.

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Pre Seed Round •••••• - 10 Jan 2023
Pre Seed Round •••••• - 01 Nov 2022
Pre Seed Round •••••• - 10 Aug 2022
Pre Seed Round •••••• - 01 Feb 2022
Pre Seed Round •••••• - 01 Dec 2021

View All 6 Funding Rounds

Brainify.AI Alternatives & Competitors

View All Alternatives
Brainify.AI vs
Merck & Co., Inc.
Merck & Co., Inc.

Merck develops and produces medicines, vaccines, biologic therapies and animal health products

IPO
92 employees
Biotechnology, Health Care
Compare Brainify.AI vs Merck & Co., Inc.
Brainify.AI vs
Paige
Paige United States

Now a Tempus company | Bridging Vision & Precision

Acquired
38 employees
Biopharma, Biotechnology
Brainify.AI vs
BioVascular Inc
BioVascular Inc

Pioneering innovative solutions for platelet-mediated cardiovascular diseases with a groundbreaking...

Series C
2-10 employees
Biotechnology, Health Care
View all alternatives

FAQ About Brainify.AI

AI biomarker platform for a novel treatment developed for depression. Part of J&J Jlabs and Merck DSS.
Brainify.AI was founded in 2021.
Brainify.AI is headquartered in New York, United States.
Brainify.AI operates in the following industries: AI, Health Care, Pharmaceutical, Machine Learning.
Brainify.AI has approximately 11 employees.
Brainify.AI has completed 6 funding rounds, raising a total of $1.60M. The latest funding stage is Pre Seed.
Brainify.AI offers: Developing and applying AI models for precision neuroscience, analyzing brain data to identify EEG biomarkers for neurological disorders and drug development..
Top alternatives and competitors to Brainify.AI include Merck & Co., Inc., Paige, BioVascular Inc, NeuroVigil, Inc., GLIA Diagnostics Pty Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Brainify.AI and Merck & Co., Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Brainify.AI and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy